ESMO 2024 – combos could be the way forward for CDK2
Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.
ESMO 2024 – Incyte tries again in anal cancer
Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.
ESMO 2024 preview – presidential focus
Second time lucky for Zynyz, Amgen’s PRMT5 comeback, and other possible surprises.
The month ahead: August’s remaining events
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
ESMO 2024 preview – Astellas unveils its KRAS degrader
ASP3082 grabs some early attention among degraders set to feature at ESMO.
The month ahead: July’s upcoming events
Earnings season begins again, while big readouts loom for ALX and Fibrogen.
